share_log

Clover Health | 8-K: Clover Health Reports Strong Third Quarter 2024 Financial Results; Highlights Differentiated Market Opportunity to Grow Membership

Clover Health | 8-K: Clover Health Reports Strong Third Quarter 2024 Financial Results; Highlights Differentiated Market Opportunity to Grow Membership

Clover Health | 8-K:三葉草健康公佈了強勁的2024年第三季度財務業績;強調了增加會員人數的差異化市場機會
美股SEC公告 ·  2024/11/06 13:12

Moomoo AI 已提取核心訊息

Clover Health delivered robust Q3 2024 financial results, with insurance revenue growing 7% YoY to $322.6 million and total revenue increasing 8.2% to $331 million. The company significantly improved its GAAP net loss from continuing operations to $8.8 million from $33.6 million in Q3 2023, while Adjusted EBITDA rose to $19.3 million from $2.7 million.The company demonstrated strong operational efficiency with Insurance BER improving to 82.8% in Q3 from 83.3% year-over-year. Year-to-date performance showed substantial improvement, with GAAP net loss from continuing operations reduced by $117.4 million and Adjusted EBITDA increased by $87.2 million compared to 2023.Based on the strong performance, Clover Health raised its full-year 2024 Adjusted EBITDA guidance to $55-65 million. The company's flagship PPO plan achieved a 4.0 Stars rating for payment year 2026, validating its care platform and positioning it for membership growth in both Insurance plans and Counterpart offering.
Clover Health delivered robust Q3 2024 financial results, with insurance revenue growing 7% YoY to $322.6 million and total revenue increasing 8.2% to $331 million. The company significantly improved its GAAP net loss from continuing operations to $8.8 million from $33.6 million in Q3 2023, while Adjusted EBITDA rose to $19.3 million from $2.7 million.The company demonstrated strong operational efficiency with Insurance BER improving to 82.8% in Q3 from 83.3% year-over-year. Year-to-date performance showed substantial improvement, with GAAP net loss from continuing operations reduced by $117.4 million and Adjusted EBITDA increased by $87.2 million compared to 2023.Based on the strong performance, Clover Health raised its full-year 2024 Adjusted EBITDA guidance to $55-65 million. The company's flagship PPO plan achieved a 4.0 Stars rating for payment year 2026, validating its care platform and positioning it for membership growth in both Insurance plans and Counterpart offering.
Clover Health 交出了強勁的2024年第三季度財務業績,保險營業收入同比增長7%至32260萬,總收入增長8.2%至33100萬。公司大幅改善了其繼續經營業務的GAAP淨虧損,從2023年第三季度的3360萬減少至880萬,而經調整的EBITDA從270萬上升至1930萬。公司展現出強大的運營效率,保險損失率(BER)在第三季度從去年的83.3%改善至82.8%。截至目前的表現顯示出顯著改善,繼續經營業務的GAAP淨虧損減少了11740萬,而經調整的EBITDA比2023年增加了8720萬。基於強勁的表現,Clover Health 將其2024年全年的經調整EBITDA指導提高至5500-6500萬。公司的旗艦PPO計劃在2026年支付年度獲得了4.0星的評級,驗證了其護理平台,併爲保險計劃和對等產品的會員增長奠定了基礎。
Clover Health 交出了強勁的2024年第三季度財務業績,保險營業收入同比增長7%至32260萬,總收入增長8.2%至33100萬。公司大幅改善了其繼續經營業務的GAAP淨虧損,從2023年第三季度的3360萬減少至880萬,而經調整的EBITDA從270萬上升至1930萬。公司展現出強大的運營效率,保險損失率(BER)在第三季度從去年的83.3%改善至82.8%。截至目前的表現顯示出顯著改善,繼續經營業務的GAAP淨虧損減少了11740萬,而經調整的EBITDA比2023年增加了8720萬。基於強勁的表現,Clover Health 將其2024年全年的經調整EBITDA指導提高至5500-6500萬。公司的旗艦PPO計劃在2026年支付年度獲得了4.0星的評級,驗證了其護理平台,併爲保險計劃和對等產品的會員增長奠定了基礎。
声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息